Oral rather than intravenous corticosteroids should be used to treat MS relapses -No James D Bowen and Peiqing Qian
Many forms of corticosteroids have been used to treat multiple sclerosis (MS) since the first clinical trial in 1961. 1 Debates about dose, route of administration, and efficacy have been heightened by demands for more convenient and cheaper therapies. A particularly important question is whether oral therapies can be substituted for intravenous corticosteroids.
The study that has most influenced the use of intravenous corticosteroids is the Optic Neuritis Treatment Trial (ONTT), a three-armed study comparing oral placebo (n = 150), methylprednisolone 250 mg intravenously four times a day for 3 days plus prednisone 1 mg/kg/day for 11 days (n = 151), or prednisone 1 mg/kg/day for 14 days (n = 156) in patients with acute optic neuritis. 2 Both corticosteroid groups had modest visual improvement compared to placebo, with methylprednisolone having a greater effect than oral prednisone, though these effects faded by 6 months. More concerning, the oral prednisone group had almost twice as many subsequent attacks of optic neuritis (27%) as the placebo (15%) or methylprednisolone (13%) groups over 24 months, and a greater proportion of people developing MS with prednisone (24%) compared to methylprednisolone (14%) or placebo (20%). Although the methodology and analysis have been criticized, 1 the ONTT suggested that oral corticosteroids alone may increase the long-term risk of subsequent demyelinating events, leading many to exclusively recommend intravenous treatment.
One of the most obvious explanations for the results of the ONTT is that they may reflect a difference in dose rather than route. The relative potency of 1000 mg methylprednisolone is equivalent to 1250 mg prednisone or 200 mg dexamethasone. 1 Some have advocated simply giving the oral equivalent doses of these three corticosteroids since the bioavailability of oral preparations is approximately 80%-90%. 3 For example, one large-scale clinical trial compared 1400 mg of oral and 1000 mg of intravenous methylprednisolone, allowing for an estimated 70% oral bioavailability. 4 This strategy, though likely better than using lower doses, betrays differences in pharmacokinetic parameters such as peak plasma concentrations and elimination half-life. Pharmacodynamic parameters such as the concentration producing half maximal effects also determine the duration and intensity of corticosteroid effects. 3 Determining equivalent doses of prednisone is difficult because of the complicated metabolism to Corticosteroids have many effects on the immune system which might be beneficial in MS. These include changes in antigen-presenting cells, decreases in T cells, shifting from T H 1 toward T H 2 bias, decreases in proinflammatory cytokines and chemokines, repression of adhesion molecules, and inhibition of matrix metalloproteinases. 3, 6 One of the most important immune effects is the induction of apoptosis in lymphocytes which helps in controlling autoreactivity as well as maintaining a balance between pro-and antiinflammatory functions. 7 Apoptosis of lymphocytes, particularly CD4+ cells, has been demonstrated in MS patients immediately after a 2-hour infusion of 500-1000 mg of methylprednisolone. 8 In an experimental autoimmune encephalomyelitis (EAE) model, 1 mg/kg methylprednisolone showed no difference in T cell apoptosis compared to controls, but 10 and 50 mg/kg doses had progressively greater effects. 9 These effects of higher dose corticosteroids were associated with higher concentrations in plasma, cerebrospinal fluid, and spinal cord tissue. In MS patients, the amount of steroids absorbed after intravenous or oral dosing (area under the curve) is similar. 10 However, peak blood levels are considerably higher with intravenous administration because of the rapid absorption of the dose. Given the rapid onset of steroid-induced apoptosis, the dependence of apoptosis on plasma and tissue concentrations, and the known differences in peak plasma concentrations, the equivalence of intravenous and oral doses based on area under the curve on the immune system cannot be assumed.
Clinical trials provide limited evidence supporting the efficacy and safety of oral corticosteroids. Total oral doses ranging from 0.6 to 5.0 g/course and intravenous doses from 2.5 to 5.0 g/course of methylprednisolone, with or without an oral taper, have been studied. 11 Outcomes are generally measured at 4 weeks with the Expanded Disability Status Scale (EDSS) or gadolinium enhancement on magnetic resonance imaging (MRI) used to determine recovery from the MS attack. More recent studies include a randomized, double-blind, controlled trial that compared 500 mg of oral or intravenous methylprednisolone. The results suggest that oral and intravenous therapies are similar, but the small sample size (n = 35), low statistical power, and possible unblinding limit the validity of the findings. 12 Ramo-Tello et al. 13 conducted a non-inferiority trial of oral versus intravenous methylprednisolone using a non-inferiority margin of 1.0. Although well executed, the 1.0 margin should be viewed with caution considering the small sample size (n = 48). The short clinical and radiological follow-up does not address potential reversibility of the effects or the long-term impact of therapy.
Recently, a 13-center, double-blind, non-inferiority trial compared 1000 mg of oral (n = 100) or intravenous methylprednisolone (n = 99) daily for 3 days given within 15 days of the onset of a relapse. 14 The primary endpoint of ⩾1 point improvement on the most affected Functional System Scale of the EDSS at day 28 was similar in those receiving oral (81%) and intravenous (80%) therapy. By 6 months, 66% of the oral and 67% of the intravenous groups recovered fully. This trial confirms similar short-term MS relapse recovery for oral and intravenous regimens but does not address long-term outcomes beyond 6 months. Patients with comorbidities were excluded, limiting applicability to wider populations. MRI assessments could provide more convincing evidence about the long-term risk of relapse following corticosteroid treatment.
Adverse effects for high-dose oral corticosteroids are not fully understood. These include insomnia, mood changes (irritability, euphoria, psychosis), gastrointestinal upset (nausea, heartburn), flushing, and weight gain. 12, 15, 16 Insomnia was more frequently reported after oral therapy, though it has lower bioavailability than the IV dose. 14 Since the effects of large numbers of pills on gastrointestinal function or effects of intravenous preparations given orally have not been studied in large numbers of patients, caution should be used until high-dose oral treatment is more widely adopted.
Although the immediate effects of high-dose oral and intravenous corticosteroids are similar for MS attacks, uncertainty regarding long-term effects, in particular the risk of late MS exacerbations, suggests that these treatments are not completely equivalent. Differences in dose, bioavailability, peak concentrations, and mechanism of action may differ between oral and intravenous corticosteroids. Current studies, though often underpowered, suggest short-term equivalence, but fail to address the long-term effects on exacerbations and adverse effects. Further research should address these issues to allow more widespread use of oral medications which have an advantage regarding cost and ease of administration.
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Despite an expanding arsenal of relapse-preventing medications, acute relapse treatment in multiple sclerosis (MS) remains a common need. Steroids have been used to treat these relapse events for decades. 1 Although there is little debate about the role of steroids in MS relapses (i.e. hastening recovery), there is no standard regarding dose route or regimen, particularly the use of oral over intravenous agents. In this
